UTHR - United Therapeutics GAAP EPS of $2.67 misses by $1.83 revenue of $491.5M misses by $27.7M

• United Therapeutics press release ( NASDAQ: UTHR ): Q4 GAAP EPS of $2.67 misses by $1.83 .
• Revenue of $491.5M (+18.4% Y/Y) misses by $27.7M .
• Net product sales from our treprostinil-based products (Tyvaso, Remodulin, and Orenitram) grew by $83.5 million, or 23%, in the fourth quarter of 2022 compared to the fourth quarter of 2021.
• Net product sales from our treprostinil-based products (Tyvaso, Remodulin, and Orenitram) grew by $271.0 million, or 19%, in 2022 compared to 2021.

For further details see: